Drug Search Results
More Filters [+]

Seliciclib

Alternative Names: seliciclib, roscovitine, r-roscovitine, al-39256
Latest Update: 2023-09-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CDK9 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cyclacel
Company Location: BERKELEY HEIGHTS NJ 07922
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Seliciclib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: ACTH-Secreting Pituitary Adenoma|Pituitary ACTH Hypersecretion|Cystic Fibrosis|Hypertension|Glaucoma, Open-Angle|Non-Small-Cell Lung Cancer

Phase 1: Oncology Solid Tumor Unspecified|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Pro52406

P2

Recruiting

ACTH-Secreting Pituitary Adenoma|Pituitary ACTH Hypersecretion

2025-08-01

CYC682-07

P1

Completed

Oncology Solid Tumor Unspecified

2019-07-16

44%

Pro35720

P2

Terminated

ACTH-Secreting Pituitary Adenoma|Pituitary ACTH Hypersecretion

2018-10-01

ROSCO-CF

P2

Terminated

Cystic Fibrosis

2018-07-26

Recent News Events